Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17423451 | 0.98 | MEN1 (0.42) | MEN1KMT2AGABRA1GABRB2PLG | |
| SCHEMBL12310473 | 0.89 | MEN1 (0.35) | MEN1KMT2AGABRA1GABRB2 | |
| SCHEMBL2280177 | 0.89 | MEN1 (0.35) | MEN1KMT2AGABRA1GABRB2 | |
| SCHEMBL20375289 | 0.80 | GAA (0.37) | — | |
| SCHEMBL20829942 | 0.80 | GAA (0.37) | — | |
| SCHEMBL16362465 | 0.80 | GAA (0.37) | — | |
| SCHEMBL8400223 | 0.79 | CHRM2 (0.40) | — | |
| SCHEMBL5949147 | 0.78 | ESR2 (0.31) | OPRL1KCNH2 | |
| SCHEMBL13547431 | 0.78 | DRD2 (0.37) | OPRL1KCNH2 | |
| SCHEMBL12068159 | 0.78 | ADORA2A (0.37) | MEN1KMT2AGABRA1GABRB2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791139-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | Dr Reddys Laboratories Ltd (IN) | 2017-11-08 | — | — | EP | disclosed |
| EP-2595483-B1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2595483-B1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2632457-B1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2632457-B1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9555050-B2 | ATX modulating agents | BIOGEN MA INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9289419-B2 | Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-03-22 | — | — | US | disclosed |
| US-9186354-B2 | Pyrrolidine derived β3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150164869-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-06-18 | — | — | US | disclosed |
| US-9045479-B2 | Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-06-02 | — | — | US | disclosed |
| WO-2012012314-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-7294636-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-11-13 | — | — | US | disclosed |
| US-7294636-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-11-13 | — | — | US | disclosed |
| US-7294636-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-11-13 | — | — | US | disclosed |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| CN-1784393-A | Chemical compounds | ASTRAZENECA AB (SE) | 2006-06-07 | — | — | CN | disclosed |
| EP-1625120-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004099178-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | CCR5, CCR2, CX3CR1 | MEN1 4834/4885KMT2A 4078/4885GABRA1 405/4885 |
| US-20150164869-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | NTRK1, MUSK, NTRK3 | MEN1 4416/4885KMT2A 3391/4885GABRA1 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.